Kombination von Clozapin und Cariprazin bei Therapieresistenter Schizophrenie

Leitlinienbasierte Empfehlungen

• Die NICE-Leitlinien (2019) empfehlen, ein zusätzliches Antipsychotikum zur Augmentation von Clozapin hinzuzufügen, wenn Clozapin-Monotherapie unwirksam war, wobei ein Medikament gewählt werden sollte, das die häufigen Nebenwirkungen von Clozapin nicht verstärkt 1
• Die World Federation of Societies of Biological Psychiatry gibt an, dass die Kombination von Clozapin mit einem anderen Antipsychotikum der zweiten Generation bei therapieresistenter Schizophrenie Vorteile gegenüber der Monotherapie haben kann 1, 2
• Die Finnischen Leitlinien bestätigen, dass einige Patienten von der gleichzeitigen Anwendung zweier Antipsychotika profitieren können 1

Sicherheitsprofil und Monitoring

• Die Fortführung des obligatorischen Clozapin-Monitorings (wöchentliche Blutbildkontrollen in den ersten 6 Monaten, dann alle 2 Wochen) ist erforderlich 3
• Es sollte eine Überwachung auf extrapyramidale Symptome, insbesondere Akathisie, durchgeführt werden, sowie eine kardiovaskuläre Überwachung auf Tachykardie, Brustschmerzen oder Dyspnoe 4
• Metabolische Parameter (Gewicht, Glukose, Lipide) sollten überwacht werden 4

Praktisches Vorgehen

• Vor Beginn der Kombination sollte sichergestellt werden, dass die Clozapin-Dosierung und Serumkonzentration adäquat sind (therapeutisches Drug-Monitoring) 4
• Es sollte eine Berücksichtigung von Faktoren erfolgen, die den Metabolismus beeinflussen (Rauchen, Koffein, CYP2D6-Polymorphismen) 4
• Medikamente, die ebenfalls das Blutbild senken können (z.B. Carbamazepin), sollten vermieden werden 3
• Bei Kombination mit Stimmungsstabilisatoren (bei schizoaffektiver Störung) sollte auf Arzneimittelinteraktionen geachtet werden 4

Clozapin Reintroduction and Combination Therapy

Introduction to Clozapin Reintroduction and Combination

• The INTEGRATE guidelines (2025) recommend Cariprazin or Aripiprazol as suitable options for persistent negative symptoms under Clozapin 5

Combination of Clozapin with Cariprazin

• Cariprazin can be added to Clozapin without discontinuing Clozapin, and a gradual cross-titration is not required 5
• The American Academy of Sleep Medicine notes that Zolpidem and Pregabalin increase the risk of sedation, confusion, and falls, especially in combination with Clozapin 6, 7

Transition from Aripiprazol to Cariprazin

• After a 7-day Aripiprazol pause, Cariprazin can be started directly, as both are D2 partial agonists and no cross-titration is necessary 8, 5

Safety Considerations for Combination Therapy

• The World Health Organization and other health organizations imply that monitoring for extrapyramidal symptoms, particularly akathisia, is necessary, as Cariprazin, as a D2/D3 partial agonist, can cause these side effects 5
• Clonazepam (Dominal) has an elimination half-life of 30-40 hours and can cause morning sedation, coordination disorders, and confusion 6, 7
• The combination of Clonazepam with Clozapin increases the risk of respiratory depression and should be used with caution 6
• Special caution is required in patients with sleep apnea, as Clonazepam (0.5-1.0 mg) can increase the risk of sleep apnea 6

Augmentation Strategies for Clozapine

Primary Augmentation Strategy

• The American Psychiatric Association recommends aripiprazole as the most strongly recommended medication to combine with clozapine when monotherapy fails, particularly for reducing residual symptoms and metabolic side effects 9, 10
• Aripiprazole 5-15 mg/day should be added as first-line augmentation to clozapine monotherapy at therapeutic levels (350-600 ng/mL) 9
• Aripiprazole can reduce metabolic side effects of clozapine, including weight gain and metabolic disturbances 9

Alternative Antipsychotic Combinations

• The World Federation of Societies of Biological Psychiatry suggests risperidone as potentially advantageous when combined with clozapine 10

Critical Prerequisites Before Augmentation

• Before adding any medication to clozapine, verify therapeutic clozapine plasma levels (350-600 ng/mL) through therapeutic drug monitoring, confirm adequate trial duration, rule out non-adherence, and assess factors affecting metabolism 9, 10
• Confirm adequate trial duration (at least two failed monotherapy trials with other antipsychotics) before adding augmentation 9
• Rule out non-adherence using long-acting injectables or blood concentration measurements before adding augmentation 9

Common Pitfalls to Avoid

• Do not add augmentation before confirming therapeutic clozapine levels and adequate trial duration 9
• Do not use antipsychotic polypharmacy as initial strategy—monotherapy should always be optimized first 10

Combining Antipsychotics for Treatment-Resistant Schizophrenia

Prerequisite Steps and Justification for Combination Therapy

• Antipsychotic polypharmacy should only be considered after documented failure of at least two adequate monotherapy trials, with the combination of aripiprazole plus clozapine being the most evidence-supported strategy for treatment-resistant schizophrenia 11
• Before adding a second antipsychotic, it is essential to confirm adequate trial duration of at least 4-6 weeks at therapeutic doses for each monotherapy attempt, and to rule out non-adherence by considering long-acting injectables or therapeutic drug monitoring 11, 12
• Ensuring clozapine has been tried as monotherapy if two other antipsychotic monotherapies have failed and no absolute contraindications exist is crucial, according to the guideline evidence 11, 12

Evidence-Supported Combinations and Their Rationale

• The American Psychiatric Association recommends combining aripiprazole with clozapine for treatment-resistant schizophrenia, as this combination may reduce residual positive and negative symptoms when clozapine monotherapy is insufficient 11
• The mechanism rationale for combining aripiprazole with clozapine is based on balanced dopaminergic modulation, with aripiprazole acting as a partial D2 agonist and clozapine as a low-potency D2 antagonist 11

Critical Safety Considerations and Monitoring

• The guideline society emphasizes the importance of not combining antipsychotics as an initial strategy, and instead recommends optimizing monotherapy first, as supported by evidence 11, 12

Aripiprazole Depot and Clozapine Concurrent Use for Treatment-Resistant Schizophrenia

Evidence and Recommendations

• The National Institute for Health and Care Excellence (NICE) guidelines allow adding another antipsychotic to augment clozapine when monotherapy proves ineffective, selecting an agent that doesn't compound clozapine's side effects 13
• The World Federation of Societies of Biological Psychiatry acknowledges that combining clozapine with another second-generation antipsychotic may have advantages in treatment-resistant cases, with approximately 70% of patients with schizophrenia requiring long-term, even lifetime medication 13

Patient Management

• Patients with schizophrenia may require long-term, even lifetime medication, with 70% of patients needing ongoing treatment 13